This bill matters to voters because it addresses a critical gap in Medicare coverage that can prevent early detection and prevention of hereditary cancers. Many cancers, like certain breast, ovarian, or colorectal cancers, have a strong genetic link, meaning they run in families due to inherited gene mutations. Identifying these mutations early through genetic testing allows individuals and their doctors to take proactive steps, such as increased surveillance or preventive surgeries, to either detect cancer at its earliest, most treatable stages or even prevent it entirely.

Without this bill, many Medicare beneficiaries with a strong family history of cancer might face significant out-of-pocket costs for genetic testing or preventive measures, or they might not pursue them at all. This could lead to a later diagnosis, more invasive treatments, and worse health outcomes. By expanding coverage, the bill could reduce the emotional and financial burden on patients and their families, improve public health outcomes by shifting from reactive treatment to proactive prevention, and potentially lower long-term healthcare costs associated with advanced cancer treatments.